Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Cited by (1,000)

Items 101–200 of 1,000

1. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
   Patrick Arnaud‐Coffin, Denis Maillet, Hui Kong Gan, Jean‐Jacques Stelmes, Benoît You, Stéphane Dalle, Julien Péron · 2019 · International Journal of Cancer
2. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
   Sree Harsha Tirumani, Nikhil H. Ramaiya, Abhishek R. Keraliya, Nancy Bailey, Patrick Alexander Ott, Frank Stephen Hodi, Mizuki Nishino · 2015 · Cancer Immunology Research
3. Checkpoint blocking antibodies in cancer immunotherapy
   Chrisann Kyi, Michael A. Postow · 2013 · FEBS Letters
4. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
   Oh, David Y., Cham, Jason, Zhang, Li, Fong, Grant, Kwek, Serena S., Klinger, Mark, Faham, Malek, Fong, Lawrence · 2017 · Cancer Research
5. Cardiotoxicity of immune checkpoint inhibitors
   Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, Gjada Criscuolo, Maria Triassi, Domenico Bonaduce, Gianni Marone, Carlo Gabriele Tocchetti · 2017 · ESMO Open
6. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
   Tom Wei‐Wu Chen, A.R. Abdul Razak, Philippe Lucien Bedard, Lillian L. Siu, Aaron Richard Hansen · 2015 · Annals of Oncology
7. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
   Yinghong Wang, Hamzah Abu‐Sbeih, Emily Mao, Noman Ali, Faisal S. Ali, Wei Qiao, Phillip J. Lum, Gottumukkala Subba Raju, Gladis A. Shuttlesworth, John Stroehlein et al. · 2018 · Journal for ImmunoTherapy of Cancer
8. Treatment Outcomes of Immune-Related Cutaneous Adverse Events
   Phillips, Gregory S., Wu, Jennifer, Hellmann, Matthew D., Postow, Michael A., Rizvi, Naiyer A., Freites-Martinez, Azael, Chan, Donald, Dusza, Stephen, Motzer, Robert J., Rosenberg, Jonathan E. et al. · 2019 · Journal of Clinical Oncology
9. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
   Yinghong Wang, Hamzah Abu‐Sbeih, Emily Mao, Noman Ali, Wei Qiao, Van Anh Trinh, Chrystia M. Zobniw, Daniel Hartman Johnson, Rashmi T. Samdani, Phillip J. Lum et al. · 2018 · Inflammatory Bowel Diseases
10. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
    Stefanie N. Linch, Michael J. McNamara, William L. Redmond · 2015 · Frontiers in Oncology
11. Acute kidney injury in patients treated with immune checkpoint inhibitors
    Shruti Gupta, Samuel Short, Meghan E. Sise, Jason M. Prosek, Sethu M. Madhavan, María José Soler, Marlies Ostermann, Sandra M. Herrmann, Ala Abudayyeh, Shuchi Anand et al. · 2021 · Journal for ImmunoTherapy of Cancer
12. Ipilimumab associated hepatitis: imaging and clinicopathologic findings
    Kyung Won Kim, Nikhil H. Ramaiya, Katherine Maragaret Krajewski, Jyothi Priya Jagannathan, Sree Harsha Tirumani, Amitabh Srivastava, Nageatte Ibrahim · 2013 · Investigational New Drugs
13. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
    Salahaldin A. Tahir, Jianjun Gao, Yuji Miura, Jorge M. Blando, Rebecca S. Slack Tidwell, Hao Zhao, Sumit Kumar Subudhi, Hussein A. Tawbi, Emily Zhi-Yun Keung, Jennifer Ann Wargo et al. · 2019 · Proceedings of the National Academy of Sciences
14. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
    Ahmad A. Tarhini · 2013 · Scientifica
15. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
    Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan · 2017 · Cancer Immunology Immunotherapy
16. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
    Braaten, Tawnie J, Brahmer, Julie R, Forde, Patrick M, Le, Dung, Lipson, Evan J, Naidoo, Jarushka, Schollenberger, Megan, Zheng, Lei, Bingham, Clifton O, Shah, Ami A et al. · 2020 · Annals of the Rheumatic Diseases
17. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
    Jonathan L. Curry, Michael T. Tetzlaff, Priyadharsini Nagarajan, Carol R. Drucker, Adi K. Diab, Sharon R. Hymes, Madeleine A. Duvic, Wen‐Jen Hwu, Jennifer Ann Wargo, Carlos Antonio Torres-Cabala et al. · 2016 · Journal of Cutaneous Pathology
18. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
    Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, Frank Stephen Hodi, Richard F. Kefford et al. · 2014 · Cancer
19. Mitigating the toxic effects of anticancer immunotherapy
    Tara C. Gangadhar, Robert H. Vonderheide · 2014 · Nature Reviews Clinical Oncology
20. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
    David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul C. Lorigan, Steven J O'Day · 2013 · Annals of Oncology
21. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
    Evan J. Lipson, Victor E. Velculescu, Theresa S. Pritchard, Mark Sausen, Drew M. Pardoll, Suzanne Louise Topalian, Luis Alberto Diaz · 2014 · Journal for ImmunoTherapy of Cancer
22. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
    Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong · 2018 · Journal for ImmunoTherapy of Cancer
23. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
    Daniel L. Suzman, Lorraine Cheryl Pelosof, Amy S. Rosenberg, Mark Avigan · 2018 · Liver International
24. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
    Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael G Kiehl, Michael Koldehoff, Stefan W. Krause et al. · 2017 · Annals of Hematology
25. Ipilimumab-associated Hepatitis
    Melanie E. Johncilla, Joseph Misdraji, Daniel Stephan Pratt, Agoston T. Agoston, Gregory Yves Lauwers, Amitabh Srivastava, Leona A. Doyle · 2015 · The American Journal of Surgical Pathology
26. Neurologic complications of immune checkpoint inhibitors
    Andreas Felix Hottinger · 2016 · Current Opinion in Neurology
27. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Rossana Franzin, Giuseppe Stefano Netti, Federica Spadaccino, Camillo Porta, Loreto Gesualdo, Giovanni Stallone, Giuseppe Castellano, Elena Ranieri · 2020 · Frontiers in Immunology
28. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
    Howard L. Kaufman, John M. Kirkwood, Frank Stephen Hodi, Sanjiv S. Agarwala, THOMAS T. AMATRUDA, Steven D. Bines, Joseph I. Clark, Brendan D. Curti, Marc S. Ernstoff, Thomas Frank Gajewski et al. · 2013 · Nature Reviews Clinical Oncology
29. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
    Daniel Hartman Johnson, Chrystia M. Zobniw, Van Anh Trinh, Junsheng Ma, Roland L. Bassett, Noha Abdel‐Wahab, Jaime E. Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Isamu Uemura et al. · 2018 · Journal for ImmunoTherapy of Cancer
30. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
    Siqi Tang, Ling‐Long Tang, Yan‐Ping Mao, Wen‐Fei Li, Lei Chen, Yuan Zhang, Ying Qiang Guo, Qing Liu, Ying Hao Sun, Cheng Xu et al. · 2020 · Cancer Research and Treatment
31. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
    Louise E. Daly, Derek Gerard Power, Aine O’Reilly, Paul P. Donnellan, Samantha J. Cushen, Kathleen O’Sullivan, ‎Maria Twomey, David P. Woodlock, Henry Paul Redmond, Aoife M. Ryan · 2017 · British Journal of Cancer
32. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
    Yago Pico de Coaña, Aniruddha Choudhury, Rolf W. Kiessling · 2015 · Trends in Molecular Medicine
33. Ipilimumab in patients with cancer and the management of dermatologic adverse events
    Mario E. Lacouture, Jedd D. Wolchok, Gil Yosipovitch, Katharina Charlotte Kähler, Klaus Johannes BUSAM, Axel Hauschild · 2014 · Journal of the American Academy of Dermatology
34. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
    on behalf of the European Conference on Infections in Leukemia (ECIL), Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiébaut, Anne Bergeron, Tomás Franquet, Nicole M. A. Blijlevens, Johan A. Maertens · 2019 · Leukemia
35. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
    Lidar, Merav, Giat, Eitan, Garelick, Daniela, Horowitz, Yuval, Amital, Howard, Steinberg-Silman, Yael, Schachter, Jacob, Shapira-Frommer, Ronnie, Markel, Gal · 2018 · Autoimmunity Reviews
36. Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
    Yan Feng, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel W. Humphrey, Jeffrey S. Weber · 2013 · Clinical Cancer Research
37. Which drug, and when, for patients with BRAF-mutant melanoma?
    Sekwon Jang, Michael B. Atkins · 2013 · The Lancet Oncology
38. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Jean‐Marie Michot, Julien Lazarovici, Ashley Tieu, Stéphane Champiat, Anne-Laure Voisin, Mikaël Ebbo, Bertrand Godeau, Marc Michel, Vincent Ribrag, Olivier Lambotte · 2019 · European Journal of Cancer
39. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
    Meagan Spencer Barbee, Adebayo Ogunniyi, Troy Z. Horvat, Thu-Oanh Dang · 2015 · Annals of Pharmacotherapy
40. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
    Takeo Fujii, Rivka R. Colen, Mehmet Asım Bilen, Kenneth R. Hess, Joud Hajjar, Maria Eugenia Suarez-Almazor, Anas Alshawa, David S. Hong, Apostolia Maria Tsimberidou, Filip Jankú et al. · 2017 · Investigational New Drugs
41. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
    Yinghao Zhao, Wei Yang, Yuanyuan Huang, Ranji Cui, Xiangyan Li, Bingjin Li · 2018 · Cellular Physiology and Biochemistry
42. CRISPR–Cas: a tool for cancer research and therapeutics
    Hao Yin, Wen Xue, Daniel G. Anderson · 2019 · Nature Reviews Clinical Oncology
43. Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
    Miguel F. Sanmamed, Lieping Chen · 2014 · The Cancer Journal
44. Immunotherapy advances for glioblastoma
    D. A. Reardon, Gordon James Freeman, Catherine J. Wu, Ennio Antonio Chiocca, Kai W. Wucherpfennig, Patrick Yung Wen, Edward F. Fritsch, William T. Curry, John Howard Sampson, Glenn Dranoff · 2014 · Neuro-Oncology
45. Advances in immunotherapy delivery from implantable and injectable biomaterials
    David G. Leach, Simon W. Young, Jeffrey D. Hartgerink · 2019 · Acta Biomaterialia
46. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
    Elizabeth L. Buchbinder, Frank Stephen Hodi · 2015 · Journal of Clinical Investigation
47. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Samantha R. Ellis, Aren T Vierra, Jillian Wong Millsop, Mario E. Lacouture, Maija H. Kiuru · 2020 · Journal of the American Academy of Dermatology
48. Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
    KM Morrissey, Theresa M. Yuraszeck, Chi‐Chung Li, Y Zhang, Sreeneeranj Kasichayanula · 2016 · Clinical and Translational Science
49. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
    Maria D’Souza, Dorte Lisbet Nielsen, Inge Marie Svane, Kasper Karmark Iversen, Peter Vibe Rasmussen, Christian Madelaire, Emil Loldrup Fosbøl, Lars Køber, Finn Gustafsson, Charlotte Andersson et al. · 2020 · European Heart Journal
50. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
    Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt Alex Schalper, Carmen Oñate, Arantza Azpilikueta, Maria Esperanza Rodriguez-Ruiz, Aizea Morales‐Kastresana, Sara Labiano, José Luis Perez‐Gracia, Salvador Martín‐Algarra et al. · 2015 · Cancer Research
51. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
    Jennifer Ann Wargo, Alexandre Reuben, Zachary Aaron Cooper, Kevin S. Oh, Ryan Joseph Sullivan · 2015 · Seminars in Oncology
52. Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
    Chrisann Kyi, Michael Andrew Postow · 2016 · Immunotherapy
53. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
    Valsamo Anagnostou, Mark M. Yarchoan, Aaron Richard Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah E. Collyar, Laura Q.M. Chow, Patrick M. Forde · 2017 · Clinical Cancer Research
54. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
    Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni, Jacopo Pigozzo, Michele Maio, Maresa Altomonte, Michele Del Vecchio, Lorenza Di Guardo, Paolo Marchetti, Ruggero Ridolfi et al. · 2014 · Journal of Translational Medicine
55. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
    Omar Mohammed Abdel-Rahman, Hani Oweira, Ulf Petrausch, Daniel Helbling, Jan Schmidt, Meinrad Mannhart, Arianeb Mehrabi, Othmar Markus Schöb, Anwar Giryes · 2017 · Expert Review of Anticancer Therapy
56. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
    Myriam N. Bouchlaka, Gail D. Sckisel, Mingyi Chen, Annie Mirsoian, Anthony Elston Zamora, Emanual Maverakis, Danice E. C. Wilkins, Kory L. Alderson, Hui‐Hua Hsiao, Jonathan M. Weiss et al. · 2013 · The Journal of Experimental Medicine
57. Immune-related adverse events in various organs caused by immune checkpoint inhibitors
    Naoko Okiyama, Ryota Tanaka · 2022 · Allergology International
58. Immune checkpoint inhibitor toxicities
    Marin-Acevedo, Julian A., Chirila, Razvan M., Dronca, Roxana S. · 2019 · Mayo Clinic Proceedings
59. Advances in immunotherapy for melanoma
    Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
60. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
    Laura C. Cappelli, Julie Renee Brahmer, Patrick M. Forde, Dung Thi Le, Evan J. Lipson, Jarushka Naidoo, Lei Zheng, Clifton O. Bingham, Ami A. Shah · 2018 · Seminars in Arthritis and Rheumatism
61. PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
    Jason J. Luke, Patrick Alexander Ott · 2015 · Oncotarget
62. Ipilimumab-Associated Colitis: CT Findings
    Kyung Won Kim, Nikhil H. Ramaiya, Katherine Maragaret Krajewski, Atul Bhanudas Shinagare, Stephanie Anne Holler Howard, Jyothi Priya Jagannathan, Nageatte Ibrahim · 2013 · American Journal of Roentgenology
63. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
    Clélia Coutzac, Julien Adam, Émilie Soularue, Michael Collins, Antoine Racine, Charlotte Mussini, Lisa Boselli, Nyam Kamsu-Kom, Christine Mateus, Mélinda Charrier et al. · 2017 · Journal of Crohn s and Colitis
64. Drug-Associated Dermatomyositis Following Ipilimumab Therapy
    Shirwa Sheik Ali, Allison L. Goddard, Jason J. Luke, Hilary Donahue, Derrick J. Todd, Andrew E. Werchniak, Ruth Ann Vleugels · 2014 · JAMA Dermatology
65. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
    Bernice Lo, Jill M. Fritz, Helen C. Su, Gülbû Uzel, Michael B. Jordan, Michael J. Lenardo · 2016 · Blood
66. Small and Large Intestine (I): Malabsorption of Nutrients
    Miguel A. Montoro, Blanca Belloc, Manuel Domínguez‐Cajal · 2021 · Nutrients
67. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
    Julia Zaragoza, Agnès Caille, N. Bénéton, Guido Bens, François Christiann, H. Maillard, L. Machet · 2015 · British Journal of Dermatology
68. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Neeraj Chhabra, Joseph M. Kennedy · 2021 · Journal of Medical Toxicology
69. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control
    Ian C. Miller, Ali H. Zamat, Lee-Kai Sun, Hathaichanok Phuengkham, Adrian M. Harris, Lena Gamboa, Jason Yang, John Paul Murad, Saul J. Priceman, Gabriel A. Kwong · 2021 · Nature Biomedical Engineering
70. Immune modulation for cancer therapy
    Jarushka Naidoo, David B. Page, Jedd D. Wolchok · 2014 · British Journal of Cancer
71. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
    Kira Minkis, Benjamin C. Garden, Shenhong Wu, Melissa P. Pulitzer, Mario E. Lacouture · 2013 · Journal of the American Academy of Dermatology
72. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
    Benjamin P. Geisler, Roy A. Raad, Diana Esaian, Elad Sharon, David R. Schwartz · 2015 · Journal for ImmunoTherapy of Cancer
73. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
    Eduard Cornelis Verschuren, Alfons J.M. van den Eertwegh, Janneke Wonders, Rob M.E. Slangen, Foke van Delft, Adriaan Anthonie Van Bodegraven, Andra Neefjes‐Borst, Nanne K.H. de Boer · 2015 · Clinical Gastroenterology and Hepatology
74. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
    Célèste Lebbé, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Omid Hamid, Steven J O'Day, Cyril Konto, Lori Cykowski, M. Brent McHenry et al. · 2014 · Annals of Oncology
75. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
    Scott, Emma S, Long, Georgina V, Guminski, Alexander, Clifton-Bligh, Roderick J, Menzies, Alexander M, Tsang, Venessa H · 2018 · European Journal of Endocrinology
76. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
    Michele Maio, Riccardo Danielli, Vanna Chiarion‐Sileni, Jacopo Pigozzo, Giorgio Parmiani, Ruggero Ridolfi, Francesco De Rosa, Michele Del Vecchio, Lorenza Di Guardo, Paola Queirolo et al. · 2013 · Annals of Oncology
77. French Endocrine Society guidance on endocrine side effects of immunotherapy
    Castinetti, F, Albarel, F, Archambeaud, F, Bertherat, J, Bouillet, B, Buffier, P, Briet, C, Cariou, B, Caron, Ph, Chabre, O et al. · 2019 · Endocrine Related Cancer
78. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
    Dipti M. Karamchandani, Runjan Chetty · 2018 · Journal of Clinical Pathology
79. Phase I trials as valid therapeutic options for patients with cancer
    Jacob J. Adashek, Patricia Mucci LoRusso, David S. Hong, Razelle Kurzrock · 2019 · Nature Reviews Clinical Oncology
80. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
    Takushi Shirai, Tasuku Sano, Fuminao Kamijo, Nana Saito, Tomomi Miyake, Minori Kodaira, Nagaaki Katoh, Kenichi Nishie, Ryuhei Okuyama, Hisashi Uhara · 2015 · Japanese Journal of Clinical Oncology
81. Endocrinological side-effects of immune checkpoint inhibitors
    Francesco Torino, Salvatore Maria Corsello, Roberto Salvatori · 2016 · Current Opinion in Oncology
82. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
    Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma · 2021 · Frontiers in Immunology
83. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 Mg/Kg within an expanded access programme
    Di Giacomo, Anna Maria, Calabrò, Luana, Danielli, Riccardo, Fonsatti, Ester, Bertocci, Erica, Pesce, Isabella, Fazio, Carolina, Cutaia, Ornella, Giannarelli, Diana, Miracco, Clelia et al. · 2013 · Cancer Immunology Immunotherapy
84. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
    Annie Ngai Man Wong, Grant A. McArthur, Michael S. Hofman, Rodney J. Hicks · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
85. Clinical assessment of immune-related adverse events
    Aaron E. Sosa, Esther Lopez Cadena, Cristina Simon Olivé, Niki Karachaliou, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
86. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
    Eileen F. Shiuan, Kathryn Eby Beckermann, Alpaslan Özgün, Ciara Marie Kelly, Meredith Ann McKean, Jennifer Leigh McQuade, Mary Ann Thompson, Igor J. Puzanov, John P. Greer, Suthee Rapisuwon et al. · 2017 · Journal for ImmunoTherapy of Cancer
87. Considerations for designing preclinical cancer immune nanomedicine studies
    Wen Jiang, Yifan Wang, Jennifer Ann Wargo, Frederick F. Lang, Betty Y.S. Kim · 2020 · Nature Nanotechnology
88. Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy
    ‪Yasmin Maor‬‏, Stephen D. H. Malnick · 2013 · International Journal of Hepatology
89. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
    Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Murakami Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku� Nomura · 2018 · International Journal of Clinical Oncology
90. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Samantha Elizabeth Bowyer, Prashanth Prithviraj, Paul C. Lorigan, James Larkin, Grant A. McArthur, Victoria G. Atkinson, Michael Millward, Muoi Khou, Stefan Diem, Sangeetha Ramanujam et al. · 2016 · British Journal of Cancer
91. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
    Remo Poto, Teresa Troiani, Gjada Criscuolo, Giancarlo Marone, Fortunato Ciardiello, Carlo Gabriele Tocchetti, Gilda Varricchi · 2022 · Frontiers in Immunology
92. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
    Weiwei Shen, Mrinal M. Patnaik, Autumn J. Ruiz, Stephen J. Russell, Kah-Whye Peng · 2015 · Blood
93. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
    Marianne J Davies, Emily Duffield · 2017 · ImmunoTargets and Therapy
94. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016)
    Ari Gnanasakthy, Amy M Barrett, Emily Evans, Denise D’Alessio, Carla DeMuro · 2019 · Value in Health
95. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.
    2017 · Cancer Research
96. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Fausto Petrelli, Giulia Grizzi, Michele Ghidini, Antonio Ghidini, Margherita Ratti, Stefano Panni, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Maria Chiara Parati et al. · 2019 · Journal of Immunotherapy
97. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
    Josefien W. Hommes, Rik Jasper Verheijden, Karijn P.M. Suijkerbuijk, Dörte Hamann · 2021 · Frontiers in Oncology
98. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    Omar Mohammed Abdel-Rahman, Mona Fouad · 2016 · Therapeutic Advances in Respiratory Disease
99. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
    Gil Redelman‐Sidi, Olivier Alain Michielin, Carlos Cervera, Camillo Ribi, José María Aguado, Mario Fernández‐Ruiz, Oriol Manuel · 2018 · Clinical Microbiology and Infection
100. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
     Yi-chi M. Kong, Jeffrey C. Flynn · 2014 · Frontiers in Immunology